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imiquimodVulvar intraepithelial neoplasia (VIN) is a premalignant disease of the vulvar squamous epithelium.
Standard treatment for VIN lesions is surgical excision. Alternative therapeutic options for conservative
treatment have been sought by patients to prevent disﬁgurement and to preserve sexual function.
We present such a patient in whom topical imiquimod was used with a successful outcome. Imiquimod
is effective in the treatment of VIN, as well as convenient, self-administered, and generally well tolerated.
© 2016 The Authors. Published by Elsevier Inc. on behalf ofWomen's Dermatologic Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Vulvar intraepithelial neoplasia (VIN) is a premalignant disease
of the squamous epithelium. It is described as a proliferation of
abnormal keratinocytes limited to the epidermis without invasion
of the basement membrane. Historically, various terms have been
used to deﬁne cancer precursors of the vulva including VIN grades
1-3 and Bowen’s disease. In 2004, the International Society for the
Study of Vulvovaginal Disease reclassiﬁed VIN to refer only to high-
grade intraepithelial lesions of the vulva, including older clinical
terms such as Bowen’s disease, dysplasia, and squamous cell carcinoma
in situ (Scurry and Wilkinson, 2006).
VIN is classiﬁed into two distinct subtypes. Usual type is associat-
ed with high-risk oncogenic human papillomavirus (HPV) infection,
cigarette smoking, and immunodeﬁciency. The less common
differentiated type typically occurs in postmenopausal women and
is associated with chronic dermatoses, including lichen sclerosis,
and HPV-negative vulvar cancer. Although VIN is an uncommon
disease, incidence is increasing, particularly in women younger than
the age of 50 years. The clinical presentation of VIN is diverse, and
patientsmay be asymptomatic or have severe pruritus, pain, burning,
and dyspareunia.r Inc. on behalf of Women's DeTreatment of VIN is indicated to decrease progression to invasive
disease along with relieving symptoms. Due to the rare incidence of
VIN, there are few large randomized studies, and consequently limit-
ed data from which to form guidelines for treatment and follow-up.
Surgery, withwide local excision or vulvectomy, is currently the stan-
dard of care for the treatment of VIN. It allows examination of tissue
margins, which is especially helpful in invasive disease. However,
surgery often results in signiﬁcant morbidity, including sexual and
psychosocial dysfunction, and is associated with a high rate of recur-
rence (Lai and Mercurio, 2010). Alternatively, medical management
of VIN has been investigated. Nonsurgical therapy may prevent dis-
ﬁgurement and preserve sexual function, but is limited to patients
with no evidence or suspicion of invasive disease on clinical exam
or biopsy. Available therapeutic options for conservative treatment
of VIN include imiquimod, cidofovir, indole-3-carbinol, photodynam-
ic therapy, and laser ablation (Hillemanns et al., 2006; Lai and
Mercurio, 2010).
Imiquimod is an immune response-modifying agent currently
FDA approved for the topical treatment of actinic keratosis, superﬁ-
cial basal cell carcinoma, and external genitalwarts. Although a num-
ber of studies support the use of topical imiquimod for the
conservative treatment of VIN, clear guidelines for optimal treatment
duration and follow-up timeline have not yet been determined. We
report a case of a woman who was diagnosed with unifocal VIN and
treated with 5% topical imiquimod cream with complete response.rmatologic Society. This is an open access article under the CC BY-NC-ND license
Fig. 1. 5×3mmwhite plaque on the right aspect of the clitoral hood during imiquimod
therapy.
Fig. 2. Pretreatment histopathology: Full-thickness involvement of the vulvar mucosa
by a proliferation of markedly atypical, hyperchromatic cells with high nuclear-to-
cytoplasmic ratio, and irregular nuclear borders. Some cells show cleared out
cytoplasm, suggesting human papillomavirus (HPV) effect (H&E, 20×).
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A 75-year-old woman was referred to our dermatology
department for an asymptomatic vulvar lesion of unknown duration.
The lesion was histologically classiﬁed as HPV-related VIN with full
thickness atypia. The patient was interested in pursuing nonsurgical
options before resorting to vulvectomy. She denied pruritus, pain,
dysuria, and dyspareunia. No prior treatments had been tried.Fig. 3. Twelve-week histopathology: Subtotal involvement of the vulvar mucosa by modera
underlying submucosa (H&E, 20×).Physical exam revealed a 5×3 mm white plaque on the right
aspect of the clitoral hood (Fig. 1). Initial biopsy of the lesion
demonstrated full-thickness marked atypia, occasional cleared
out cytoplasm (haloes), and parakeratosis, most consistent with
HPV-related VIN (Fig. 2).
Treatment was initiated with topical imiquimod 5% cream, ﬁve
times per week, for 12 weeks. The lesion was re-evaluated after 12
weeks of treatment and repeat biopsywas performed. Subsequent bi-
opsy showedmoderate to severe squamous dysplasia conﬁned to the
basal cell layer with an intense lichenoid inﬂammatory reaction
(Fig. 3). No VINwas seen.We repeated an additional course of topical
imiquimod 5% cream, ﬁve times per week for an additional 12weeks.
Shave biopsy after 24 weeks of imiquimod therapy demonstrated
lichenoid dermatitis with no residual dysplasia or carcinoma
(Fig. 4). Side effects included local irritation, pain, and candidal infec-
tion during the course of treatment. Treatment was stopped and pa-
tient was evaluated at 3, 6, and 9 months without signs and
symptoms of recurrence (Fig. 5).
Discussion
Imiquimod, a heterolytic imidazoquinoline amide, is an
effective alternative to surgery for the treatment of VIN. Classiﬁed
as an immune response-modifying drug, imiquimod enhances local
skin immune responses by activating toll-like receptor-7 and -8
on macrophages and dendritic cells, which induces the release of
pro-inﬂammatory T-helper cell type 1 cytokines (interferon-α,
interleukin-2, interleukin-12) and upregulates cell-mediated immu-
nity (Sauder, 2000). This results in an antiviral and proapoptotic
effect on HPV-infected abnormal cells. Side effects include local
pruritus, pain, burning, irritation, and soreness, which are generally
well tolerated. Patients with biopsy-proven invasive disease are
excluded from medical management. Surgical treatment should be
considered for lesions that do not respond to medical therapy.
A number of studies support the use of topical imiquimod as the
conservative treatment of choice for women with VIN (Table 1). In
a review of three clinical trials, the frequency of application of
imiquimod 5% cream ranged from two to three times weekly, with
some studies employing slow frequency escalation (Le et al., 2007;
Mathiesen et al., 2007; van Seters et al., 2008). The duration of
treatment lasted 16 weeks in all studies, and follow up ranged from
2 months to more than 7 years. The results of these studies
demonstrated complete response rates ranging from 30 to 81%,
partial response from 9.5 to 38%, and no response from 9 to 30%.
Based on a reviewof the literature, small (b1 cm) lesions aremore
likely to demonstrate a complete response to imiquimod treatment.
However, treatment periods in the randomized controlled trials
may have been too short to be effective for larger (N5 cm) lesions.
A signiﬁcant association was seen between the local skin reaction
achieved and complete disease regression. Those that reached a
higher degree of local irritation had a better likelihood of observed
complete response to treatment (Le et al., 2007). Another potential
predictive marker of imiquimod response includes viral clearance,
as complete histologic regression of lesions strongly correlates with
HPV clearance (p b .001) (van Seters et al., 2008). Patients withte to severe squamous dysplasia. Intense lichenoid inﬂammatory inﬁltrate noted in the
Fig. 4. Twenty-four week histopathology: Vulvar mucosa with mild lichenoid dermatitis. No signiﬁcant cytologic atypia or dysplasia is present (H&E, 20×).
Fig. 5. Clearance of lesion 12 weeks after completion of treatment.
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number of immune cells (CD1a+ dendritic cells, CD8+ T cells, and
CD94+natural killer cells) in the epidermis with completion of ther-
apy. Total amount of imiquimod used did not correlatewith observed
response to treatment or recurrence rate (Le et al., 2007). Lesion dis-
tribution (unifocal vs. multifocal) has not been associated withTable 1
Imiquimod for the Treatment of Vulvar Intraepithelial Neoplasia: Review of the Literature
Source No. of
patients
(T/C)
Treatment method Pathologic regre
CR Tn (%)/Cn (%
Mathiesen et al. (2007) 21/10 16 weeks: qWeek for 2 weeks,
BIW following 2 weeks,
TIW last 12 weeks.
Biopsy taken 2 months
after end of treatment.
17 (81)/0⁎
Le et al. (2007) 33 16 weeks: qWeek for 2 weeks,
BIW following 2 weeks,
TIW last 12 weeks.
Biopsy taken at end of
16 week treatment.
21 (64)/NM
Van Seters et al. (2008) 26/26 16 weeks: BIW for 16 weeks.
Biopsy taken at end of 20 weeks
8 (30)/0
Terlou et al. (2011) 24/- Long-term follow-up of CR in van
Seters et al. for at least 5 years
-
BIW, twice per week; CR, complete response; NM, not mentioned; NR, no response; PR, part
times per week
⁎ p b .001.
† p= .013.treatment response (p = .66) (Le et al., 2007). Imiquimod cream is
able to upregulate the immune response, not only in areaswith direct
contact to the topical, but also in adjacent areas, which is advanta-
geous when skip lesions may be present.
In addition to effects on histologic regression, imiquimod reduces
pruritus and pain associatedwith VIN (p=.008 and p=.004, respec-
tively) (van Seters et al., 2008). In patients with a partial response to
imiquimod, clinically signiﬁcant decreased lesion size may be seen,
leading to surgical resection with better-preserved sexual function
and improved cosmetic result.
An additional beneﬁt of imiquimod is the continued
immunostimulant effect on the area after treatment, preventing
HPV expression and VIN recurrence. Terlou et al. (2011) report on
the 7-year follow-up of 24 of 26 patients treated with imiquimod in
their original study (van Seters et al., 2008). Of the complete re-
sponders, eight of nine had no recurrence of VIN. One patient had re-
currence of VIN 4 years after demonstrating a complete response to
imiquimod. Le et al. (2007) demonstrated a signiﬁcantly lower rate
of recurrence and longer time to recurrence compared with primary
surgically treated patients (p= .013). Prognostic variables related to
VIN recurrence include age at diagnosis, smoking, and HPV status. A
signiﬁcantly higher recurrence rate is seen in women aged 65 or
older compared with that of women younger than age 65 years
(p= .03) (Westermann et al., 2013). All ﬁve patients who had recur-
rence after complete response to imiquimod in Le et al. (2007) had a
smoking history of at least one pack per day. VIN recurrence rate is
also higher in women with initial HPV-negative disease. Despite the
immunostimulant effect, follow-up visits to monitor for recurrence
and long-term effects should be employed and biopsy of suspicious
areas should be performed for all patients.ssion Mean
follow
up (mo)
No. of
recurrences
(CR/C)
Progression
to invasive
disease
(CR/C)
) PR Tn (%)/Cn (%) NR Tn (%)/Cn (%)
2 (9.5)/0 2 (9.5)/0 2 NM 0/0
9 (27)/NM 3 (9)/NM 16 5 (24)/NM (54)† 0
10 (38)/(4) 8 (30)/25(96) 12 0/NM 0/2
- - 86 1 (11) 0
ial response; qWeek, once per weekly; T/C, treatment group/control group; TIW, three
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rence or vulvar cancer throughout their lifetime. Post-treatment surveillance
has been limited in most studies. Van Seters et al. (2008) performed post-
treatment assessments at 7 and 12months. In womenwith a complete re-
sponse to imiquimod therapy, we recommend follow up at 3, 6, and 12
months with annual visits thereafter given the slow rate of progression.
In conjunction with the results of these studies, our experience con-
ﬁrmed topical imiquimod is effective in the treatment of VIN. Imiquimod is
effective, convenient, self-administered, andwell tolerated. Invasive disease
must be ruled out before starting imiquimod therapy. Ideal candidates for
imiquimod therapy include nonsmoking, HPV-positive patients younger
thanage65yearswith small lesions. A longerdurationof treatment is need-
ed for patients with larger lesions. Slow dose escalation and frequent clinic
visits to provide reassurance resulted in improved tolerability and successful
completion of the treatment regimen. A thorough follow-up regimen is rec-
ommended tomonitor for recurrence and progression to invasive disease.
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